Trumbull News Detail
Kent State College of Public Health Awarded $50,000 Grant for Biofilm ResearchPosted Mar. 11, 2013
Kent State University’s College of Public Health recently received the National Science Foundation’s Small Business Innovation Grant while partnering with Sterionics Inc. for work on advancing and commercializing a wound therapy biotechnology product.
The grant totaled $150,000; $50,000 of which went to Kent State, the remainder to Sterionics.
Principal investigator Christopher Woolverton, Ph.D., professor of environmental health science, and James Ferrell, biological sciences graduate student, have been collaborating with Sterionics since 2008. The subcontract to Kent State will extend bench research on the Sterionics device, which uses proprietary technology to kill bacteria.
“Our partnership has not only supported the research and development of Sterionics, but also permitted a Kent State graduate student access to technology and business workings, allowing him to see the inner workings of a small company,” says Woolverton.
Sterionics, a science technology and innovation company, and Kent State have collaborated for several years on developing a product that is aimed at killing bacteria and biofilms, a thin film of bacteria that sticks to a surface. The device has also demonstrated the ability to stimulate skin cell growth. It kills bacteria that cause skin infections while stimulating cells that make up the skin to reproduce rapidly and migrate, which is determined by laboratory testing.
“It’s like a one-two punch,” says Ferrell.
Kent State and Sterionics are currently working on phase one of the project. The goal is to put prototype one to use, further modifying it to make it smaller and to optimize it by “tuning” it for specific applications.
Ferrell says he is optimistic that the results generated from this grant will result in positive data for the phase one proposal and ultimately lead to phase two funding from the National Science Foundation’s Small Business Innovation Research program.
Phase two could eventually lead to controlled animal trials with this technology. The overarching goal of all of this work is to lead to commercialization and advancement of wound care.
“The partnership between Kent State University and small businesses like Sterionics could lead to positive and mutual benefits for both entities moving into the future,” says Ferrell.
For more information, contact Woolverton at email@example.com.